2. Disease Areas
  3. Cancer
  4. Skin Cancer
  5. Mutant Melanoma

Mutant Melanoma

Mutant melanoma is characterized by a high mutational burden, primarily driven by ultraviolet radiation and other mutational processes. Genomic analysis of 333 melanoma patients revealed four distinct genomic subtypes: BRAF-mutant, NRAS-mutant, NF1-mutant, and triple-wildtype. While BRAF-mutant melanomas are effectively targeted by BRAF and MEK inhibitors, the other subtypes—NRAS-mutant, NF1-mutant, and triple-wildtype—remain largely undruggable with currently available targeted therapies.

Mutant Melanoma (9):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-D3140
    MB-m-borate
    MB-m-borate is a double-locked near-infrared fluorescence-activated probe (Ex/Em ≈ 647 nm/684 nm). MB-m-borate undergoes cascade activation by hydrogen peroxide and tyrosinase to release the fluorophore methylene blue, thereby generating a fluorescence activation response. MB-m-borate enables precise detection of melanoma in melanoma cells and mouse models. MB-m-borate can be used for melanoma research.
    MB-m-borate
  • HY-P991952
    ADU-1604
    ADU-1604 is a humanized IgG1 CTLA-4 antibody. ADU-1604 binds to a unique epitope on CTLA-4 and achieves full blockade of both CD80 and CD86 interactions. ADU-1604 enhances human T cell responses. ADU-1604 demonstrates a favorable tolerability profile. ADU-1604 can be used for melanoma research. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    ADU-1604
  • HY-155801
    CRX 527 216014-14-1
    CRX 527 is a TLR4 agonist. CRX 527 activates the MyD88-dependent, TRIF-dependent, and TRAF6/NF-κB signaling pathways downstream of TLR4, mimics lipid A, and regulates antigen processing and presentation by dendritic cells. CRX 527 stimulates innate immune responses and enhances vaccine efficacy. CRX 527 maintains the structural integrity of hematopoietic tissues, spleen and intestine, alleviates radiation-induced damage, preserves intestinal homeostasis, and inhibits apoptosis, inflammatory responses, oxidative stress and DNA damage. CRX 527 can be used in the research of acute radiation syndrome, melanoma, HPV-related tumors and intracerebral hemorrhage.
    CRX 527
  • HY-185121
    PROTAC CDK2/4/6 Degrader-2 2541626-49-5
    PROTAC CDK2/4/6 Degrader-2 is a CDK2/4/6 PROTAC degrader. PROTAC CDK2/4/6 Degrader-2. PROTAC CDK2/4/6 Degrader-2 can be converted into the prodrug PROTAC CDK2/4/6 Degrader-1 (HY-171826) through a one-step reaction with chloromethyl pivalate. PROTAC CDK2/4/6 Degrader-2 degrades CDK2/4/6 and their complex in malignant melanomas cells. PROTAC CDK2/4/6 Degrader-2 induces cell cycle arrest and cell apoptosis in various cancer cells, in particular for melanomas. PROTAC CDK2/4/6 Degrader-2 can be used for malignant melanomas research.
    PROTAC CDK2/4/6 Degrader-2
  • HY-183629
    ZNF281-IN-1
    ZNF281-IN-1 is a ZNF281 inhibitor. ZNF281-IN-1 disrupts the binding of transcriptionally active DNA-bound ZNF281 to the promoters of target genes including TRIM35 and ZEB1. ZNF281-IN-1 inhibits tumor cell proliferation, stabilizes P53 and upregulates PUMA to induce apoptosis, while triggering cellular senescence. ZNF281-IN-1 completely prevents Doxorubicin (HY-15142A)-induced cardiotoxicity (AIC), and enhances rather than impairs the antitumor efficacy of Doxorubicin. ZNF281-IN-1 completely blocks the distant metastasis of melanoma to the lungs. ZNF281-IN-1 can be used in the research of cardiotoxicity, lung cancer and metastatic melanoma.
    ZNF281-IN-1
  • HY-181131
    Anticancer agent 300 1310059-06-3
    Anticancer agent 300 (compound P14) is a CCND1, CDK4, CDK6, and CCNE1 modulator, with anti-proliferative, cell-cycle modulatory, senescence-inducing, and apoptosis-inducing activity. Anticancer agent 300 can be used for the research of ER+/HER2− breast cancer and BRAF-mutant melanoma.
    Anticancer agent 300
  • HY-N17617
    S-Petasin 70238-51-6
    S-Petasin is a phosphodiesterase (PDE) inhibitor with IC50 values of 25.5 μM and 17.5 μM for PDE3 and PDE4, respectively. S-Petasin inhibits cholesterol side-chain cleavage enzyme, 11β-hydroxylase, PPAR-γ, and iNOS induction at RNA and protein levels. S-Petasin induces apoptosis, activates caspases, cleaves PARP, modulates mitochondrial membrane permeability, and regulates BCL2/BAX, p53, Bcl-XL, MMP-2, MMP-9, p21, CDK4, and cyclin D1 expression. S-Petasin reduces inflammatory cell accumulation, cytokine and IgE levels, and enhances serum IgG2a levels. S-Petasin relaxes isolated sensitized guinea pig trachealis and exhibits gastrointestinal anti-spasmodic activity. S-Petasin reduces tonsillitis severity and asthmatic attack frequency. S-Petasin can be used for the research of prostate cancer, obesity, melanoma, allergic asthma, asthma, and peritonitis.
    S-Petasin
  • HY-181130
    Anticancer agent 299 1414873-26-9
    Anticancer agent 299 (compound P12) is a cell-cycle inhibitor, senescence inducer, apoptosis inducer, and antiproliferative agent. Anticancer agent 299 exhibits selective activity against cancer cells with minimal effects on non-tumoral chondrocyte cells at relevant concentrations. Anticancer agent 299 can be used for the research of ER+/HER2− breast cancer and BRAF-mutant melanoma.
    Anticancer agent 299
  • HY-180419
    SF-3-030 1883721-73-0
    SF-3-030 is a potent, selective and non-ATP competitive ERK1/2 inhibitor. SF-3-030 selectively induces apoptosis in melanoma cells containing mutated BRaf and constitutively active ERK1/2 signalling. SF-3-030 mitigates multiple features of asthma in a murine model of asthma. SF-3-030 can be used for the research of asthma and melanomasup.
    SF-3-030